Structural modulation of the gut microbiota and the relationship with body weight: compared evaluation of liraglutide and saxagliptin treatment
Open accessThe DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Abstract
The mechanisms underlying the weight-loss effect of GLP-1 receptor agonists need further elucidation. The present study was performed to explore the effects of liraglutide and saxagliptin on the composition of the gut microbiota. Mice were randomly treated with saxagliptin or liraglutide for eight weeks. Their metabolic profiles were assessed, and 454 pyrosequencing of 16s rRNA of faeces was performed. Liraglutide induced a smaller body weight gain in mice. The pyrosequencing showed that liraglutide, but not saxagliptin, substantially changed the overall structure of the gut microbiota as well as the relative abundance of weight-relevant phylotypes. Subsequent ridge regression analyses indicated that, in addition to food intake (β = −0.182, p = 0.043 in phylotypes inversely correlated with body weight) and blood glucose level (β = −0.240, p = 0.039 in phylotypes positively correlated with body weight), the administration of liraglutide was another independent factor associated with the abundance of weight-relevant phylotypes (β = 0.389, p = 6.24e-5 in inversely correlated ones; β = −0.508, p = 2.25e-5 in positively correlated ones). These results evidenced that GLP-1 receptor agonist liraglutide could modulate the composition of the gut microbiota, leading to a more lean-related profile that was consistent with its weight-losing effect.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The authors [42] observed that liraglutide (but not saxagliptin) causes a lower expression of obesity-related philotypes (including Roseburia, Erysipelotrichaceae Incertae Sedis, Marvinbryantia and Parabacteroides), while on the contrary it promotes the growth of the philotypes Blautia and Coprococcus, which are related to a lower body mass index.”
From GLP-1 receptor agonists and renal outcomes in patients with diabetes mellitus type 2 and diabetic kidney disease: state of the art (2022) · cites this paper as [42]
In the citing paper
“The authors [42] observed that liraglutide (but not saxagliptin) causes a lower expression of obesity-related philotypes (including Roseburia, Erysipelotrichaceae Incertae Sedis, Marvinbryantia and Parabacteroides), while on the contrary it promotes the growth of the philotypes Blautia and Coprococcus, which are related to a lower body mass index.”
From GLP-1 receptor agonists and renal outcomes in patients with diabetes mellitus type 2 and diabetic kidney disease: state of the art (2022) · cites this paper as [42]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Schloss, P. D., Westcott, S. L., Ryabin, T., Hall, J. R., Hartmann, M., Hollister, E. B., Lesniewski, R. A., Oakley, B. B., Parks, D. H., Robinson, C. J., et al. (2009) · Applied and Environmental Microbiology · doi:10.1128/aem.01541-09 · Cited by 19,549
UPARSE: highly accurate OTU sequences from microbial amplicon reads
Edgar, R. C. (2013) · Nature Methods · doi:10.1038/nmeth.2604 · Cited by 16,707
Metagenomic biomarker discovery and explanation
Segata, N., Izard, J., Waldron, L., Gevers, D., Miropolsky, L., Garrett, W. S., & Huttenhower, C. (2011) · Genome Biology · doi:10.1186/gb-2011-12-6-r60 · Cited by 16,192
An obesity-associated gut microbiome with increased capacity for energy harvest
Turnbaugh, P. J., Ley, R. E., Mahowald, M. A., Magrini, V., Mardis, E. R., & Gordon, J. I. (2006) · Nature · doi:10.1038/nature05414 · Cited by 12,444
The Elements of Statistical Learning: Data Mining, Inference, and Prediction
John Lu, Z. Q. (2010) · Journal of the Royal Statistical Society Series A: Statistics in Society · doi:10.1111/j.1467-985x.2010.00646_6.x · Cited by 12,390
Statistical significance for genomewide studies
Storey, J. D., & Tibshirani, R. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1530509100 · Cited by 9,692
Human gut microbes associated with obesity
Ley, R. E., Turnbaugh, P. J., Klein, S., & Gordon, J. I. (2006) · Nature · doi:10.1038/4441022a · Cited by 8,785
UniFrac: a New Phylogenetic Method for Comparing Microbial Communities
Lozupone, C., & Knight, R. (2005) · Applied and Environmental Microbiology · doi:10.1128/aem.71.12.8228-8235.2005 · Cited by 8,227
Enterotypes of the human gut microbiome
MetaHIT Consortium (additional members), Arumugam, M., Raes, J., Pelletier, E., Le Paslier, D., Yamada, T., Mende, D. R., Fernandes, G. R., Tap, J., Bruls, T., et al. (2011) · Nature · doi:10.1038/nature09944 · Cited by 7,548
Obesity alters gut microbial ecology
Ley, R. E., Bäckhed, F., Turnbaugh, P., Lozupone, C. A., Knight, R. D., & Gordon, J. I. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0504978102 · Cited by 6,176
Cited by
Discrepant gut microbiota markers for the classification of obesity-related metabolic abnormalities
Zeng, Q., Li, D., He, Y., Li, Y., Yang, Z., Zhao, X., Liu, Y., Wang, Y., Sun, J., Feng, X., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-49462-w · Cited by 408
The gut microbiota in obesity and weight management: microbes as friends or foe?
Van Hul, M., & Cani, P. D. (2023) · Nature Reviews Endocrinology · doi:10.1038/s41574-022-00794-0 · Cited by 318
Effects of Synbiotic Supplement on Human Gut Microbiota, Body Composition and Weight Loss in Obesity
Sergeev, I. N., Aljutaily, T., Walton, G., & Huarte, E. (2020) · Nutrients · doi:10.3390/nu12010222 · Cited by 331
Modulatory Effects of Probiotics During Pathogenic Infections With Emphasis on Immune Regulation
Raheem, A., Liang, L., Zhang, G., & Cui, S. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.616713 · Cited by 302
Drug-microbiota interactions: an emerging priority for precision medicine
Zhao, Q., Chen, Y., Huang, W., Zhou, H., & Zhang, W. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01619-w · Cited by 268
“378 Interestingly, another research demonstrated that liraglutide increased the Bacteroides -to- Firmicutes ratio to decrease body weight in both simply overweight and diabetes-overweight individuals independent of glycaemic condition.”
BackgroundWestern diets, gut dysbiosis, and metabolic diseases: Are they linked?
Martinez, K. B., Leone, V., & Chang, E. B. (2017) · Gut Microbes · doi:10.1080/19490976.2016.1270811 · Cited by 271
“Mechanisms behind the beneficial effects of dietary fiber include SCFA production (discussed previously), stimulation of intestinal gluconeogenesis, increased epithelial integrity, release of hormones PYY and GLP1 to promote satiety and insulin sensitivity, increased expression of antimicrobial peptides, and alteratio…”
BackgroundGut microbiota influence in type 2 diabetes mellitus (T2DM)
Cunningham, A. L., Stephens, J. W., & Harris, D. A. (2021) · Gut Pathogens · doi:10.1186/s13099-021-00446-0 · Cited by 270
Wang, Y., Dilidaxi, D., Wu, Y., Sailike, J., Sun, X., & Nabi, X.-H. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.109914 · Cited by 270
Gut microbiome in type 1 diabetes: A comprehensive review
Zheng, P., Li, Z., & Zhou, Z. (2018) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3043 · Cited by 228
“The previous literature showed that several drugs commonly used in the treatment of type 2 diabetes, such as metformin, liraglutide, and saxagliptin, had an impact on the composition of gut microbiome.(84,85) Insulin administration is commonly used in patients with T1D, but whether insulin treatment can affect gut mic…”
BackgroundLongo, S., Rizza, S., & Federici, M. (2023) · Acta Diabetologica · doi:10.1007/s00592-023-02088-x · Cited by 194
“In humans, prebiotic treatment increases microbiome diversity, and consequently GLP-1 levels and satiety [73, 74].”
BackgroundIntestinal microbiome and NAFLD: molecular insights and therapeutic perspectives
Hu, H., Lin, A., Kong, M., Yao, X., Yin, M., Xia, H., Ma, J., & Liu, H. (2020) · Journal of Gastroenterology · doi:10.1007/s00535-019-01649-8 · Cited by 208
GLP-1 receptor agonists and kidney protection
Greco, E., Russo, G., Giandalia, A., Viazzi, F., Pontremoli, R., & De Cosmo, S. (2019) · Medicina · doi:10.3390/medicina55060233 · Cited by 173
“Nonetheless, there are some data linking the composition of the gut microbiome with kidney disease [35].”
BackgroundCrosstalk between glucagon-like peptide 1 and gut microbiota in metabolic diseases
Zeng, Y., Wu, Y., Zhang, Q., & Xiao, X. (2023) · mBio · doi:10.1128/mbio.02032-23 · Cited by 195
“The GLP-1 RA liraglutide, but not saxagliptin (129), changed the overall structure of the gut microbiota, especially some bacteria related to glucolipid metabolism and intestinal inflammation (130, 131).”
BackgroundLiraglutide modulates gut microbiota and reduces NAFLD in obese mice
Moreira, G., Azevedo, F., Lm, R., Santos, A., Guadagnini, D., Gama, P., Liberti, E., Saad, M., & Carvalho, C. (2018) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2018.07.009 · Cited by 169
Considering gut microbiota in treatment of type 2 diabetes mellitus
Adeshirlarijaney, A., & Gewirtz, A. T. (2020) · Gut Microbes · doi:10.1080/19490976.2020.1717719 · Cited by 174
“Liraglutide substantially altered the overall composition of the gut microbiota, consistent with its weight-lowering effect.(56) Abundance of genera including Allobaculum, Turicibacter, Anaerostipes, Blautia, Lactobacillus, Butyricimonas and Desulfovibrio was enriched, while Clostridiales and Bacteroidales were dimini…”
ResultKanbay, M., Onal, E. M., Afşar, B., Dağel, T., Yerlikaya, A., Covic, A. C., & Vaziri, N. D. (2018) · International Urology and Nephrology · doi:10.1007/s11255-018-1873-2 · Cited by 162
“Also, the development of diabetic microangiopathy can further compromise intestinal mucosal perfusion, thereby perturbing intestinal barrier function [52], and amplifying gut microbial dysbiosis [102] as observed in ischemia–reperfusion injury.”
BackgroundZhao, L., Chen, Y., Xia, F., Abudukerimu, B., Zhang, W., Guo, Y., Wang, N., & Lu, Y. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00233 · Cited by 165
GLP-1 Receptor Agonists and Diabetic Kidney Disease: A Call of Attention to Nephrologists
Górriz, J. L., Soler, M. J., Navarro-González, J. F., García-Carro, C., Puchades, M. J., D’Marco, L., Martínez Castelao, A., Fernández-Fernández, B., Ortiz, A., Górriz-Zambrano, C., et al. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9040947 · Cited by 144
“Treatment with GLP-1RA is able to modulate the microbiome of mice; accordingly, liraglutide could modulate the composition of the gut microbiota, leading to a more lean-related profile that was consistent with its weight-losing effect [65].”
BackgroundGut-Brain Axis: Role of Microbiome, Metabolomics, Hormones, and Stress in Mental Health Disorders
Verma, A., Inslicht, S. S., & Bhargava, A. (2024) · Cells · doi:10.3390/cells13171436 · Cited by 159
“Glucagon-like peptide-1 (GLP-1) receptor agonists are medications for diabetes mellitus that have a beneficial side effect of significant weight loss, but their long-term impact on weight gain and mental health remains unclear [225].”
BackgroundEffects of Antidiabetic Drugs on Gut Microbiota Composition
Montandon, S., & Jornayvaz, F. (2017) · Genes · doi:10.3390/genes8100250 · Cited by 135
“Firmicutes to Bacteroidetes ↓a [16] ↓a [17] ↑a [18] ↑a [18] SCFA-producing bacteria ↑h [19–21], a [22] ↑h [23,24] ↑↓a [17] Firmicutes ↓a [17] ↑a [18] ↓↑a [18] Clostridiales (order) ↑h [24] ↓a [18] Anaerostipes ↑a [18] Anaerotruncus ↓a [25] Blautia ↑a [22]↓a [25] ↓a [17] ↑a [18] Butyricicoccus ↑a [22] ↓h [24] Butyrivib…”
Hu, X.-F., Zhang, W., Wen, Q., Chen, W., Wang, Z., Chen, J., Zhu, F., Liu, K., Cheng, L., Yang, J., et al. (2018) · Pharmacological Research · doi:10.1016/j.phrs.2018.11.042 · Cited by 142
“Previous research demonstrated that microbial richness and diversity were reduced in disease groups, such as hypertension and obesity [20,21].”
BackgroundModulating the Microbiota as a Therapeutic Intervention for Type 2 Diabetes
Huda, M. N., Kim, M., & Bennett, B. J. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.632335 · Cited by 142
Madsen, M. S. A., Holm, J. B., Pallejà, A., Wismann, P., Fabricius, K., Rigbolt, K., Mikkelsen, M., Sommer, M., Jelsing, J., Nielsen, H. B., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-52103-x · Cited by 121
Bi-directional drug-microbiome interactions of anti-diabetics
Whang, A., Nagpal, R., & Yadav, H. (2018) · EBioMedicine · doi:10.1016/j.ebiom.2018.11.046 · Cited by 136
“• Relative abundance of all obesity-related phylotypes (in the genera Erysipelotrichaceae Incertae Sedis, Marvinbryantia, Roseburia, Candidatus Arthomitus, and Parabacteroides) substantially decreased under Liraglutide administration 69 DPP-4 inhibitors Rodent: ApoE−/− C57BL/6 mice N = 60 • Saxagliptin had neutral eff…”
BackgroundInfluentialDeng, X., Zhang, C., Wang, P., Wei, W., Shi, X., Wang, P., Yang, J., Wang, L., Tang, S., Fang, Y., et al. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac210 · Cited by 126
“It has also been reported that several antidiabetic drugs such as metformin, acarbose, and liraglutide partly achieve their glucose-lowering effects and additional metabolic improvements by modulating the gut microbiota and its metabolites (12-15).”
BackgroundSelf-citationGLP-1 and GLP-2 Orchestrate Intestine Integrity, Gut Microbiota, and Immune System Crosstalk
Abdalqadir, N., & Adeli, K. (2022) · Microorganisms · doi:10.3390/microorganisms10102061 · Cited by 119
Onal, E. M., Afşar, B., Covic, A. C., Vaziri, N. D., & Kanbay, M. (2018) · Hypertension Research · doi:10.1038/s41440-018-0144-z · Cited by 121
“Additionally, use of liraglutide and saxagliptin has been reported to improve the Lactobacillaceae level in the gut flora [235].”
BackgroundThe potential and pitfalls of GLP-1 receptor agonists for renal protection in type 2 diabetes
Thomas, M. C. (2017) · Diabetes & Metabolism · doi:10.1016/s1262-3636(17)30069-1 · Cited by 111
Alteration of gut microbiota induced by DPP-4i treatment improves glucose homeostasis
Liao, X., Song, L., Zeng, B., Liu, B., Qiu, Y., Qu, H., Zheng, Y., Long, M., Zhou, H., Wang, Y., et al. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2019.03.057 · Cited by 103
“In addition, a previous study has also reported that the microbial composition in HFD mice was changed after liraglutide treatment, and that it was different from that in Sax-treated HFD mice [38].”
ResultCheng, M., Liang, J., Zhang, Y., Hu, L., Gong, P., Cai, R., Zhang, L., Zhang, H., Ge, J., Ji, Y., et al. (2017) · Frontiers in Microbiology · doi:10.3389/fmicb.2017.00837 · Cited by 98
Microbiota and Diabetes Mellitus: Role of Lipid Mediators
Salazar, J. J., Angarita, L., Morillo, V., Navarro, C., Martínez, M. S., Chacín, M., Torres, W., Rajotia, A., Rojas, M., Cano, C., et al. (2020) · Nutrients · doi:10.3390/nu12103039 · Cited by 106
The Relationships between Gut Microbiota and Diabetes Mellitus, and Treatments for Diabetes Mellitus
Crăciun, C.-I., Neag, M. A., Cătinean, A., Mitre, A. O., Rusu, A., Bala, C. G., Román, G., Buzoianu, A. D., Muntean, D. M., & Craciun, A. E. (2022) · Biomedicines · doi:10.3390/biomedicines10020308 · Cited by 105
Effects of GLP-1 Analogues and Agonists on the Gut Microbiota: A Systematic Review
Gofron, K. K., Wasilewski, A., & Małgorzewicz, S. (2025) · Nutrients · doi:10.3390/nu17081303 · Cited by 90
“Wang L et al. [18] presented a decrease in diversity based on Shannon’s and Simpson’s indices in normoglycemic mice, while in hyperglycemic mice, it was restored to a normal level after treatment.”
Zhang, M., Feng, R., Yang, M., Cheng, Q., Wang, Z., Liu, W., & Ma, J. (2019) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2019-000717 · Cited by 93
“Wang et al showed that the genera Lactobacillus, Allobaculum and Turicibacter were also enriched following liraglutide and saxagliptin dosage.(29) 30 There was little research on the taxonomic composition of sitagliptin.”
BackgroundGut microbiota, hypertension and chronic kidney disease: Recent advances
Sircana, A., Michieli, F. D., Parente, R., Framarin, L., Leone, N., Berrutti, M., Paschetta, E., Bongiovanni, D., & Musso, G. (2018) · Pharmacological Research · doi:10.1016/j.phrs.2018.01.013 · Cited by 96
Smits, M. M., Fluitman, K. S., Herrema, H., Davids, M., Kramer, M. H. H., Groen, A. K., Belzer, C., de Vos, W. M., Cahen, D. L., Nieuwdorp, M., et al. (2021) · Diabetes & Metabolism · doi:10.1016/j.diabet.2021.101223 · Cited by 75
Li, H., Liang, J., Han, M., & Gao, Z. (2024) · Journal of Advanced Research · doi:10.1016/j.jare.2024.03.004 · Cited by 90
Satiety: a gut–brain–relationship
Barakat, G. M., Ramadan, W., Assi, G., & Khoury, N. B. E. (2024) · The Journal of Physiological Sciences · doi:10.1186/s12576-024-00904-9 · Cited by 82
“More specifically, a previous study showed that liraglutide can, in fact, alter the makeup of the gut microbiota by boosting the lean-related profile, which is consistent with its ability to reduce body weight in mice with streptozotocin-induced transient hyperglycemia [27].”
BackgroundCrosstalk between gut microbiota and antidiabetic drug action
Kyriachenko, Y., Falalyeyeva, T. M., Korotkyi, O., Molochek, N., & Kobyliak, N. M. (2019) · World Journal of Diabetes · doi:10.4239/wjd.v10.i3.154 · Cited by 85
Peng, W., Yi, P., Yang, J., Xu, P., Wang, Y., Zhang, Z., Huang, S., Wang, Z., & Zhang, C. (2018) · Aging · doi:10.18632/aging.101693 · Cited by 86
“The gut microbiota of the mice was first determined with 16S rRNA sequencing analysis as described previously [42, 43].”
MethodDiabetes-induced mechanophysiological changes in the small intestine and colon
Zhao, M., Liao, D., & Zhao, J. (2017) · World Journal of Diabetes · doi:10.4239/wjd.v8.i6.249 · Cited by 84
Shang, J., Liu, F., Zhang, B., Dong, K., Lu, M., Jiang, R., Xu, Y., Diao, L., Zhao, J., & Tang, H. D. (2021) · PeerJ · doi:10.7717/peerj.11128 · Cited by 82
“, 2018), and blood glucose and body weight were much lower after being treated with liraglutide (Wang et al., 2016).”
BackgroundGupta, S., & Sen, U. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.104391 · Cited by 83
Liu, W., Luo, Z., Zhou, J., & Sun, B. (2022) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2022.853771 · Cited by 77
Thomas, M. C., Coughlan, M. T., & Cooper, M. E. (2023) · Cell Metabolism · doi:10.1016/j.cmet.2023.01.004 · Cited by 56
Zouiouich, S., Loftfield, E., Huybrechts, I., Viallon, V., Louca, P., Vogtmann, E., Wells, P. M., Steves, C. J., Herzig, K., Menni, C., et al. (2021) · Diabetologia · doi:10.1007/s00125-021-05464-w · Cited by 69
“microbial alterations and attenuation of the metabolic syndrome after various weight-loss interventions [33, 34].”
BackgroundPectin mediates the mechanism of host blood glucose regulation through intestinal flora
Guo, Q., Hou, X., Cui, Q., Li, S., Shen, G., Luo, Q., Wu, H., Chen, H., Liu, Y., Chen, A., et al. (2023) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2023.2173719 · Cited by 67
“GLP-1 acts on pancreatic β cells to stimulate insulin secretion to regulate glucose homeostasis (Wang et al. 2016).”
BackgroundEffects of GLP-1 receptor agonist on changes in the gut bacterium and the underlying mechanisms
Kato, S., Sato, T., Fujita, H., Kawatani, M., & Yamada, Y. (2021) · Scientific Reports · doi:10.1038/s41598-021-88612-x · Cited by 59
Type 2 diabetes, gut microbiome, and systems biology: A novel perspective for a new era
Martínez-López, Y. E., Esquivel-Hernandez, D. A., Sánchez-Castañeda, J. P., Neri-Rosario, D., Guardado‐Mendoza, R., & Reséndis-Antonio, O. (2022) · Gut Microbes · doi:10.1080/19490976.2022.2111952 · Cited by 65
“Furthermore, Lactobacillus showed inhibitory activity against DPP-4, through increased incretins and glucose homeostasis.(96)”
BackgroundThe Role of the Microbiome in Drug Response
Pryor, R. E., Martínez‐Martínez, D., Quintaneiro, L. M., & Cabreiro, F. (2019) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010919-023612 · Cited by 59
Cabello-Olmo, M., Oneca, M., Torre, P., Sáinź, N., Moreno-Aliaga, M. J., Guruceaga, E., Cano, J. V. D., Encío, I., Barajas, M. A., & Araña, M. (2019) · Nutrients · doi:10.3390/nu11102530 · Cited by 64
“and microbial products such as long-chain triglycerides [70] and short chain fatty acids (SCFAs) [71], and parameters like BFG, insulin level, HOMA-IR, and weight loss [56,72].”
BackgroundPharmacologic and Nonpharmacologic Therapies for the Gut Microbiota in Type 2 Diabetes
Caesar, R. (2019) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2019.01.007 · Cited by 58
Gut microbiota and therapy for obesity and type 2 diabetes
Zhang, L., Wang, P., Huang, J., Xing, Y., Wong, F. S., Suo, J., & Li, W. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1333778 · Cited by 74
“…, and Proteobacteria , which were obesity-related phylotypes and an increase in Akkermansia , Blautia , Lactobacillus Parabacteroides and Coprococcus , which were lean-related phylotypes (61, 62), with Akkermansia muciniphila contributing to intestinal health and glucose homeostasis (84).”
BackgroundGranata, A., Maccarrone, R., Anzaldi, M., Leonardi, G., Pesce, F., Amico, F., Gesualdo, L., & Corrao, S. (2022) · Clinical Kidney Journal · doi:10.1093/ckj/sfac069 · Cited by 54
“The authors [42] observed that liraglutide (but not saxagliptin) causes a lower expression of obesityrelated philotypes (including Roseburia, Erysipelotrichaceae Incertae Sedis, Marvinbryantia and Parabacteroides), while on the contrary it promotes the growth of the philotypes Blautia and Coprococcus, which are relate…”
The Interplay between Immune System and Microbiota in Diabetes
Moffa, S., Mezza, T., CEFALO, C. M. A., Cinti, F., Impronta, F., Sorice, G. P., Santoro, A., Giuseppe, G. D., Pontecorvi, A., & Giaccari, A. (2019) · Mediators of Inflammation · doi:10.1155/2019/9367404 · Cited by 55
“showed that in mice treated with liraglutide, compared to saxagliptin, a lean-related gut microbiota profile was consistent with the loss of body weight [84].”
BackgroundShao, J., Liu, Y., Wang, H., Luo, Y., & Chen, L. (2020) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2020/1805418 · Cited by 57
“Oxidative stress and inflammation can aggravate IR [40].”
BackgroundThe Role of Glucagon-Like Peptide-1 in Energy Homeostasis
Salehi, M., & Purnell, J. Q. (2019) · Metabolic Syndrome and Related Disorders · doi:10.1089/met.2018.0088 · Cited by 46
Atzeni, A., Bastiaanssen, T. F. S., Cryan, J. F., Tinahones, F. J., Vioqué, J., Corella, D., Fitó, M., Vidal, J., Moreno‐Indias, I., Gómez‐Pérez, A. M., et al. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.804455 · Cited by 61
Cao, T. T. B., Wu, K., Hsu, J., Chang, C., Chou, C., Lin, C.-Y., Liao, Y.-M., Lin, P.-C., Yang, L., & Lin, H. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.573891 · Cited by 54
“In terms of β-diversity, there was higher cumulative evidence of significant difference after using metformin (5, 36– 39, 41, 43–50, 54–56), and similar results were consistently reported among those studies treated with acarbose (5, 58– 61), liraglutide (60, 65, 66, 69, 70), sitagliptin (5, 60, 73), and”
ResultInfluentialEffects of Oral Glucose-Lowering Agents on Gut Microbiota and Microbial Metabolites
Wang, D., Liu, J. Y., Zhou, L., Zhang, Q., Li, M., & Xiao, X. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.905171 · Cited by 52
“Compared with that in GLP-1 receptor agonist liraglutidetreated mice, the gut microbiota differed substantially in mice treated with DPP-4 inhibitors, indicating that the hypoglycemic mechanism of DPP-4 inhibitors on gut microbiota is at least not primarily by GLP-1 and the other potential benefit of DPP-4 inhibitors…”
Enterorenal crosstalks in diabetic nephropathy and novel therapeutics targeting the gut microbiota
Ni, Y., Zheng, L., Nan, S., Ke, L., Fu, Z., & Jin, J. (2022) · Acta Biochimica et Biophysica Sinica · doi:10.3724/abbs.2022140 · Cited by 49
“In addition, saxagliptin increased the F/B ratio and the relative abundance of Lactobacillus; simultaneously, the respective rise and fall of Allobaculum and Prevotella appeared to be at odds with therapeutic efficacy [148] (Table 2).”
BackgroundAhmed, I. A. B. (2024) · Journal of Obesity · doi:10.1155/2024/8056440 · Cited by 52
“Similarly, it was discovered that the intestinal microbiota contributes signifcantly to human health through its regulation of body constitution, weight management, and diabetes prevention [32–34].”
Yin, Y., Sripetchwandee, J., Chattipakorn, N., & Chattipakorn, S. C. (2021) · Anaerobe · doi:10.1016/j.anaerobe.2021.102361 · Cited by 45
Orlistat‐Induced Gut Microbiota Modification in Obese Mice
Ke, J., An, Y., Cao, B., Lang, J., Wu, N., & Zhao, D. (2020) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2020/9818349 · Cited by 50
“Furthermore, liraglutide resulted in more lean-related microbial phenotypes [31, 32].”
Woo, Y. S., Lim, H. K., Wang, S., & Bahk, W. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21186969 · Cited by 47
“Substantial rearrangement of the bacterial structure was observed in mice treated with liraglutide [182].”
BackgroundType 2 Diabetes and the Microbiome
Barlow, G. M., & Mathur, R. (2022) · Journal of the Endocrine Society · doi:10.1210/jendso/bvac184 · Cited by 49
“For example, liraglutide treatment significantly increased SCFA-producing taxa in a diabetic rat model [102], and enriched for genera including Allobaculum, Blautia, Desulfovibrio and Lactobacillus while reducing the abundance of orders Clostridiales (phylum Firmicutes) and Bacteroidales (phylum Bacteroidetes) in mice…”
BackgroundRochoń, J., Kalinowski, P., Szymanek-Majchrzak, K., & Grąt, M. (2024) · World Journal of Gastroenterology · doi:10.3748/wjg.v30.i23.2964 · Cited by 44
“In patients with T2DM and NAFLD, diabetes medications could be used, such as pioglitazone and GLP-1 RAs[122].”
Obesity, Motility, Diet, and Intestinal Microbiota—Connecting the Dots
Fayfman, M., Flint, K. L., & Srinivasan, S. (2019) · Current Gastroenterology Reports · doi:10.1007/s11894-019-0680-y · Cited by 39
Kant, R., Chandra, L., Verma, V. K., Nain, P., Bello, D., Patel, S., Ala, S., Chandra, R., & Antony, M. A. (2022) · World Journal of Methodology · doi:10.5662/wjm.v12.i4.246 · Cited by 39
Role and effective therapeutic target of gut microbiota in NAFLD/NASH (Review)
Liu, Q., Liu, S., Chen, L., Zhao, Z., Du, S.-X., Dong, Q., Xin, Y., & Xuan, S. (2019) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2019.7781 · Cited by 51
Gong, B., Li, C., Shi, Z., Wang, F., Dai, R., Chen, G., & Su, H. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1675552 · Cited by 36
Xiong, C., Wu, J., Ma, Y., Li, N., Wang, X., Li, Y., & Ding, X. (2024) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s451129 · Cited by 37
“36,37 Consistent with the aforementioned results, most bacteria that showed a positive relationship with body weight in the current correlation analysis belong to the phylum Bacteroidota.”
ResultGLP‐1 agonists and the gut microbiome: A bidirectional relationship
Kamath, S., Chan, N. S. L., & Joyce, P. M. (2026) · British Journal of Clinical Pharmacology · doi:10.1002/bcp.70487 · Cited by 42
Yang, C., Liu, S., Li, H., Bai, X., Shan, S., Gao, P., & Dong, X. (2021) · Aging · doi:10.18632/aging.203095 · Cited by 34
“We performed 16S rRNA sequencing analysis of human feces as previously described [34, 35].”
Methodda Silva, R. S., de Paiva, I. H. R., Mendonça, I. P., de Souza, J. R. B., Lucena‐Silva, N., & Peixoto, C. A. (2024) · Inflammopharmacology · doi:10.1007/s10787-024-01603-y · Cited by 39
“Treatments with GLP-1R agonists such as liraglutide, dulaglutide, and semaglutide induce an increase in the proportion of Bacteroidetes to Firmicutes, as well as gut microbes related to the lean phenotype (Blau-tia and Akkermansia) (Wang et al. 2016, 2018; Hupa-Breier et al. 2021; Duan et al. 2024).”
Lupien‐Meilleur, J., Andrich, D. E., Quinn, S., Micaelli-Baret, C., St-Amand, R., Roy, D., & St-Pierre, D. H. (2019) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2019.10.006 · Cited by 38
Zhang, N., Tao, J., Gao, L., Bi, Y., Li, P., Wang, H., Zhu, D., & Feng, W. (2020) · BioMed Research International · doi:10.1155/2020/2947549 · Cited by 37
Self-citationGlaros, S. B., Mishra, S. P., Jain, S., Davis, F., Gabel, S. A., Mueller, G. A., Jarmusch, A. K., Mabundo, L. S., Courville, A. B., Walter, M. F., et al. (2025) · Gut Microbes · doi:10.1080/19490976.2025.2558071 · Cited by 32
“Liraglutide enriched intestinal bacterial communities and promoted SCFA-producing species in mice 31 and adult humans, 9,32 though the mechanisms for these changes remain elusive.”
Wang, Z., Wang, J., Hu, J., Chen, Y., Dong, B., & Wang, Y. (2021) · Life Sciences · doi:10.1016/j.lfs.2021.119069 · Cited by 31
Chen, F., He, L., Li, J., Yang, S., Zhang, B., Zhu, D., Wu, Z., Zhang, S., Hou, D., Ouyang, C., et al. (2022) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2022.879294 · Cited by 32
Does Gut-Microbiome Interaction Protect against Obesity and Obesity-Associated Metabolic Disorders?
Zawada, A. E., Rychter, A. M., Ratajczak, A. E., Lisiecka-Masian, A., Dobrowolska, A., & Krela‐Kaźmierczak, I. (2020) · Microorganisms · doi:10.3390/microorganisms9010018 · Cited by 30
“No effects of sitagliptin have been observed [66].”
BackgroundCrosstalk between gut microbiota and osteoarthritis: A critical view
Korotkyi, O., Kyriachenko, Y., Kobyliak, N. M., Falalyeyeva, T. M., & Остапченко, Л. І. (2020) · Journal of Functional Foods · doi:10.1016/j.jff.2020.103904 · Cited by 31
Ding, Q., Tian, J., Li, M., Lian, F., Zhao, L., Wei, X., Han, L., Zheng, Y., Gao, Z., Yang, H., et al. (2020) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2020.530160 · Cited by 30
Zhang, X., Ren, H., Zhao, C., Shi, Z., Li, Q., Yang, F., Zhou, X., Han, X., Wu, K., Zhong, H., et al. (2022) · Diabetologia · doi:10.1007/s00125-022-05768-5 · Cited by 30
“The moderate effect of 6 month vildagliptin treatment on the human gut microbiota, however, differed considerably from the existing findings using rodent models [6, 7, 41, 42].”
BackgroundGut microbiota and type 2 diabetes mellitus: a focus on the gut-brain axis
Pan, Y., Bu, T., Deng, X., Jia, J., & Yuan, G. (2024) · Endocrine · doi:10.1007/s12020-023-03640-z · Cited by 31
“Liraglutide administration could modulate the GM to a more lean-related composition in diabetic mice [115].”
Gastrointestinal Motility Effects of GLP-1 Receptor Agonists
Bellavance, D. R., Chua, S. G., & Mashimo, H. L. (2025) · Current Gastroenterology Reports · doi:10.1007/s11894-025-00995-3 · Cited by 31
Microbiota: A potential orchestrator of antidiabetic therapy
Liu, B., Zhang, L., Yang, H., Zheng, H., & Liao, X. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.973624 · Cited by 31
D’Marco, L., Morillo, V., Górriz, J. L., Suarez, M., Nava, M., Ortega, Á., Parra, H., Villasmil, N., Rojas, J., & Bermúdez, V. (2021) · Journal of Diabetes Research · doi:10.1155/2021/9032378 · Cited by 33
“Thus, cardioprotective and renoprotective effects could be an indirect result of the role of GLP-1RA over classic renal and cardiovascular risk factors, such as glycemic control, weight loss [96, 97], blood pressure [98], and decrease of serum LDLcholesterol and triacylglycerides [99], and even the modulation of the i…”
BackgroundChemoproteomic identification of a DPP4 homolog in Bacteroides thetaiotaomicron
Keller, L. J., Nguyen, T. H., Liu, L. J., Hurysz, B. M., Lakemeyer, M., Guerra, M., Gelsinger, D. J., Chanin, R., Ngo, N., Lum, K. M., et al. (2023) · Nature Chemical Biology · doi:10.1038/s41589-023-01357-8 · Cited by 24
“One caveat is that the mice in the diabetes model were treated for 8 weeks with saxagliptin 40 , as opposed to the single 48-h dose we applied to in vitro communities.”
InfluentialThe role of incretins and incretin-based drugs in autoimmune diseases
Radbakhsh, S., Atkin, S. L., Simental‐Mendía, L. E., & Sahebkar, A. (2021) · International Immunopharmacology · doi:10.1016/j.intimp.2021.107845 · Cited by 24
Camastra, S., Astiarraga, B., Tura, A., Frascerra, S., Ciociaro, D., Mari, A., Gastaldelli, A., & Ferrannini, E. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12836 · Cited by 23
Ma, X., Qiu, Y., Mao, M., Lu, B., Zhao, H., Pang, Z., & Li, S. (2023) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2023.117627 · Cited by 23
Effect of metformin and metformin/linagliptin on gut microbiota in patients with prediabetes
Martínez-López, Y. E., Neri-Rosario, D., Esquivel-Hernandez, D. A., Padrón-Manrique, C., Vázquez-Jiménez, A., Sánchez-Castañeda, J. P., Giron-Villalobos, D., Mendoza-Ortíz, C., Reyes‐Escogido, M. D. L., Evia-Viscarra, M. L., et al. (2024) · Scientific Reports · doi:10.1038/s41598-024-60081-y · Cited by 22
“…et al. explored GM modulation by liraglutide (GLP-1 receptor agonist) and saxagliptin (DPP-4i); they reported increased levels of Lactobacillus, Allobaculum, and Turicibacter in mice treated with saxagliptin, indicating possible increment in incretins and their effect on glucose homeostasis 32 .”
BackgroundDiTaxa: nucleotide-pair encoding of 16S rRNA for host phenotype and biomarker detection
Asgari, E., Münch, P. C., Lesker, T. R., McHardy, A. C., & Mofrad, M. R. K. (2018) · Bioinformatics · doi:10.1093/bioinformatics/bty954 · Cited by 20
Zhang, Z., Du, Z., Liu, Q., Wu, T., Tang, Q., Zhang, J., Huang, C., Huang, Y., Li, R., Li, Y., et al. (2021) · Metabolism · doi:10.1016/j.metabol.2021.154728 · Cited by 21
Bidirectional Interactions Between the Gut Microbiota and Incretin-Based Therapies
Trapanese, V., Dagostino, A., Natale, M. R., Giofrè, F., Vatalaro, C., Melina, M., Cosentino, F., Sergi, S., Imoletti, F., Spagnuolo, R., et al. (2025) · Life · doi:10.3390/life15060843 · Cited by 25
“…C57BL/6 ApoE/mice (half of which received streptozotocin) and randomised to 8 weeks of treatment with liraglutide or saxagliptin revealed that only the former substantially modified the composition of the intestinal microbiota, particularly the concentration of phylotypes relevant to weight [68].”
Neuromodulatory effect of microbiome on gut-brain axis; new target for obesity drugs
Ejtahed, H., & Hasani‐Ranjbar, S. (2019) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-019-00384-4 · Cited by 19
GLP-1 receptor agonists in IBD: exploring the crossroads of metabolism and inflammation
Migliorisi, G., Gabbiadini, R., Buono, A. D., Ferraris, M., Privitera, G., Petronio, L., Bertoli, P., Bezzio, C., & Armuzzi, A. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1610368 · Cited by 26
Dong, Y., Wu, J., Chang, C., Lin, J., Wu, L., & Toh, S. (2022) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2688 · Cited by 16
Cabello-Olmo, M., Oneca, M., Urtasun, R., Pajares, M. J., Goñi, S., Riezu‐Boj, J. I., Milagro, F. I., Ayo, J., Encío, I., Barajas, M. A., et al. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15041203 · Cited by 17
“Contrary to our findings, previous works on Goto-Kakizaki rats [85] and HFD-fed rats [86] found that both metformin and berberine increased Allobaculum abundance, and the same effect was found with other antidiabetic drugs [87] and probiotic treatments [31].”
Result
Metadata
- Authors
- Wang, L., Li, P., Tang, Z., Yan, X., & Feng, B.
- Affiliations
- Tongji University (CN)
- Corresponding author
- Feng, Bo
- Venue
- Scientific Reports
- Published
- 2016-09-16
- Volume
- 6
- Issue
- 1
- Pages
- 33251-33251
- ISSN
- 2045-2322 (ISSN-L)
- PMC
- PMC5025740
- OpenAlex
- W2519618698
- Cited by
- 165
- References
- 37
- Citations by year
- 2026: 14 · 2025: 16 · 2024: 16 · 2023: 19 · 2022: 19 · 2021: 19 · 2020: 20 · 2019: 22 · 2018: 12 · 2017: 6 · 2016: 2
- FWCI
- 7.27
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Scientific Reports (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- Chinese Medical Association (2011CB504006, 12030510351, PWZz2013-04)
- National Key Research and Development Program of China (2011CB504006, PWZz2013-04, 12030510351)
- Fundamental Research Funds for the Central Universities (1507219042)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Keywords
- gut microbiota, liraglutide, saxagliptin, GLP-1 receptor agonists, body weight, weight loss, microbiota composition, dietary intake, blood glucose, 16S rRNA gene sequencing, ridge regression
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Gastrointestinal Microbiome, Liraglutide, Glucagon-Like Peptide-1 Receptor Agonists, Adamantane, Animals, Blood Glucose, Body Weight, Diabetes Mellitus, Experimental, Dipeptides, DNA, Bacterial, Eating, Feces, Hyperglycemia, Hypoglycemic Agents, Male, Mice, Inbred C57BL, RNA, Ribosomal, 16S, Streptozocin, Gene Expression, Mice, Knockout, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.